Profound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third Quarter

Core Viewpoint - Profound Medical Corp. anticipates significant revenue growth for Q3 2025, with preliminary estimates indicating revenues between $5.2 million and $5.3 million, representing an increase of 84% to 87% compared to the same period last year [2][3] Financial Performance - For the quarter ended September 30, 2025, Profound expects total revenues in the range of $5.2 million to $5.3 million, up from $2.8 million in Q3 2024 [2] - The gross margin for Q3 2025 is projected to be approximately 72%, an increase from 64% in the prior year [2] Business Developments - The installed base of the TULSA-PRO system has grown to 67 units, up from 60, with expectations to reach at least 75 by the end of the year due to a strong capital sales pipeline [3] - The TULSA Procedure is positioned as a potential mainstream treatment for various prostate conditions, emphasizing its incision-free and radiation-free nature [6] Upcoming Events - The company will release its full Q3 2025 financial results on November 13, 2025, followed by a conference call at 4:30 p.m. ET to discuss the results and business developments [4]